IGC Pharma

We are a clinical stage pharmaceutical company, formerly known as India Globalization Capital, Inc.

About IGC Pharma (dba IGC):

IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Clinical data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.

03/31/2026

To enhance visibility across investor audiences, IGC Pharma has partnered with New to The Street, a financial media platform known for its integrated investor engagement and national television distribution.

The campaign will feature IGC Pharma on New to The Street’s sponsored programming on Fox Business and Bloomberg Television and will be amplified through digital channels, outdoor billboard placements, and earned media distribution across major U.S. broadcast affiliates.

The Company believes participation in such platforms supports broader market awareness while maintaining a focus on disciplined clinical ex*****on and scientific development.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-launches-strategic-national-120000699.html

03/26/2026

The CALMA Clinical Trial team recently joined the Autumn Is Here podcast hosted by Francine Crawford, a platform dedicated to supporting caregivers and raising awareness around aging and Alzheimer’s disease.

Barbara Forero, Clinical Recruitment Coordinator, and Margarita Venegas, Psychometric Training & Site Feasibility Manager, shared insights into the purpose of the CALMA clinical trial, its focus on agitation in Alzheimer’s disease, participant safety, and what researchers hope to learn through ongoing studies.

We’re grateful for the opportunity to connect with caregiver communities and contribute to thoughtful conversations around Alzheimer’s research.

Listen to the full episode here: https://www.youtube.com/watch?v=uXguYFQb08I

03/20/2026

Today at AD/PD - Advances in Science & Therapy 2026, the IGC Pharma AI team presented aha™ (Agentic Harmonization Assistant) at the Alzheimer's Disease Data Initiative (ADDI) booth.

aha™ is designed to address one of the core challenges in Alzheimer’s research: integrating fragmented datasets across institutions and modalities. By harmonizing tabular and neuroimaging data, it supports cross-cohort analysis and AI-ready research at scale.

We are proud to collaborate with ADDI, reflecting a shared commitment to scalable, interoperable data solutions for the global research community.

aha™ was recently recognized as a semifinalist in the Alzheimer’s Insights AI Prize, a global initiative by ADDI to accelerate AI-driven discovery.

Strengthening research infrastructure is essential to advancing Alzheimer’s science.

03/20/2026

IGC Pharma announced the filing of its Report on Form 10-KT for the nine months ended December 31, 2025, reflecting a transition period defined by clinical acceleration, asset optimization, and continued advancement of its proprietary AI and therapeutic programs.

During the period, the Company expanded the Phase 2 CALMA trial across key sites, improved net loss attributable to common stockholders to $4.1 million compared to $5.9 million in the prior-year period and strengthened its intellectual property portfolio.

Investors and stakeholders may access the filing through the SEC or the Investor Relations section of IGC Pharma’s website.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-reports-financial-results-130000922.html?pl2=qsp-recent-news_All

03/19/2026

Data harmonization remains one of the most time-consuming steps in Alzheimer’s research, often requiring months of manual preparation before meaningful analysis can begin.

At ADPD 2026, IGC Pharma will demonstrate its Agentic Harmonization Assistant (aha™) within the Alzheimer’s Disease Data Initiative (ADDI) ecosystem.

Advanced data integration capabilities such as aha™ is designed to enhance analysis of complex clinical datasets and support the continued development of the Company’s lead drug candidate, IGC-AD1, currently being evaluated in the ongoing Phase 2 CALMA clinical trial for agitation associated with Alzheimer’s disease.

Read the full press release: https://finance.yahoo.com/news/igc-pharma-showcase-ai-platform-130000465.html?pl2=qsp-recent-news_All

03/18/2026

At AD/PD - Advances in Science & Therapy 2026, the IGC Pharma AI team is joining global researchers and innovators in discussions around data integration and research infrastructure in Alzheimer’s disease.

As part of the conference, the team will present a live demonstration of aha™ (Agentic Harmonization Assistant) on Friday at the Alzheimer’s Disease Data Initiative (ADDI) booth.

aha™ is a multimodal harmonization platform designed to integrate tabular and neuroimaging datasets to support scalable, cross-cohort research.

We look forward to engaging with the scientific community throughout the week and continuing conversations on building stronger data foundations for Alzheimer’s research.

03/11/2026

Behind every step forward in Alzheimer’s research is a team of people united by purpose.

Across departments, from research and technology to operations, individuals work side by side, learning from one another, asking important questions, and collaborating with care and intention.

It’s this shared commitment that helps move innovation forward, always with patients and families at the heart of what we do.

03/08/2026

On International Women’s Day, we recognize the women across IGC Pharma whose leadership and expertise contribute to advancing our work every day.

From research and technology to strategy and operations, their perspectives strengthen collaboration, inspire innovation, and help move Alzheimer’s research forward with purpose and care.

Today, we celebrate their impact and the progress made possible through their dedication and leadership.

03/03/2026

The brain doesn’t work alone.

Researchers are learning that gut health may play a role in Alzheimer’s disease, opening new ways of thinking about how the body and brain are connected.

By studying these connections, science continues to deepen our understanding of Alzheimer’s and the many factors involved in this complex disease.

Learn more in our Science Spotlight: https://igcpharma.com/healing-from-within-gut-health-strategies-that-may-slow-alzheimers-progression/

02/27/2026

Utility patent applications have been filed to protect key elements of IGC Pharma’s Agentic Harmonization Assistant (AHA), which is being designed as a structured, multi-stage architecture intended to automate dataset alignment and validation across diverse Alzheimer’s datasets.

Earlier this year, AHA advanced to the semi-final round of a competitive AI research evaluation program. The Company plans to present additional details regarding AHA’s development roadmap at the upcoming ADPD conference.

Read the full press release: https://finance.yahoo.com/news/igc-pharma-files-utility-patent-133000755.html

02/26/2026

IGC Pharma announced that Ascendiant Capital Markets has issued an updated equity research report covering the Company. According to Ascendiant Capital Markets, the report raises its price target to $5.00 per share.

All statements, opinions, estimates, projections, and conclusions contained in analyst reports represent the views of the respective analysts and are not those of IGC Pharma. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.

A copy of the updated report can be obtained directly from Ascendiant Capital Markets:https://cdn.aelieve.com/04c1e37f-igc-2026.02.23-q3-fy26-preview-fireside-chat.pdf

02/25/2026

Ascendiant Capital Markets has issued an updated equity research report covering IGC Pharma, raising its price target to $5.00 per share.

All statements, opinions, estimates, projections, and conclusions contained in analyst reports represent the views of the respective analysts and are not those of IGC Pharma. By referring to these analysts or distributing their opinions, IGC does not commit itself to the validity of such information, conclusions, or recommendations.

Read the full report:https://cdn.aelieve.com/04c1e37f-igc-2026.02.23-q3-fy26-preview-fireside-chat.pdf

Address

Potomac, MD

Telephone

+13019830998

Website

https://igcpharma.com/

Alerts

Be the first to know and let us send you an email when IGC Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.